By Joel Ottosson and Justyna Lisowska, PhD, Genedata This content is brought to you by Genedata, a Danaher Operating Company. Biopharma R&D is moving into a new phase shaped by intelligent AI agents that can reason, interact with data systems, and support complex scientific decisions. Their potential is enormous—from uncovering disease biology to shaping trial designs in real time—but readiness across the industry varies widely.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile